(Q37863463)

24 August 2017

1 reference

title

Management of Huntington's disease: role of tetrabenazine (English)

1 reference

24 August 2017

0 references

Marina de Tommaso

1

1 reference

24 August 2017

Claudia Serpino

series ordinal

2

1 reference

24 August 2017

Vittorio Sciruicchio

series ordinal

3

1 reference

24 August 2017

21 March 2011

1 reference

Therapeutics and Clinical Risk Management

24 August 2017

1 reference

24 August 2017

7

1 reference

24 August 2017

123-129

1 reference

Creative Commons Attribution-NonCommercial 3.0 Unported

24 August 2017

start time

1 March 2011

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Huntington's disease: from molecular pathogenesis to clinical treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Role of tetrabenazine for Huntington's disease-associated chorea

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine is neuroprotective in Huntington's disease mice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study. Huntington Study Group/TETRA-HD Investigators

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Dopaminergic signaling and striatal neurodegeneration in Huntington's disease

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine treatment in movement disorders

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Characterization of the monoamine carrier of chromaffin granule membrane by binding of [2-3H]dihydrotetrabenazine

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

A Double Blind Trial of Lithium Carbonate and Haloperidol in Huntington's Chorea

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration: the role of p25/cyclin-dependent kinase 5.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Huntington disease: functional capacities in patients treated with neuroleptic and antidepressant drugs

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine induces acute dystonic reactions

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Serum haloperidol concentration and choreiform movements in Huntington's disease

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

The long-term effect of tetrabenazine in the management of Huntington disease

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine has properties of a dopamine receptor antagonist.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Unified Huntington's disease rating scale: Reliability and consistency

1 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3071349

Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine

3 December 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21479143

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21479143

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

The metabolism of 2-chloro-11-(4-methyl-1-piperazinyl) dibenzo-(b,f)(1,4)-thiazepine (clotiapine). 3. The metabolism and excretion in the human

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21479143

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2147/TCRM.S17152

1 reference

24 August 2017

1 reference

24 August 2017

PubMed publication ID

21479143

1 reference